Not a substrate for CYPs 2C9 or 3A4. Probably not inducer or inhibitor of CYPs 2C9 or 3A4. Side effects as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Dacarbazine is a synthetic analog of the naturally occurring purine precursor 5-amino-1H-imidazole-4-carboxamide.

Dacarbazine is an antimetabolite antineoplastic agent used to treat malignant melanoma with metastases, or as part of combination therapy in advanced Mb Hodgkin. Administered as an intravenous infusion. Common adverse reactions of dacarbazine that can be confused with an acute porphyric attack are nausea, vomiting, and influenza-like symptoms.

Significant

Metabolized in the liver through hydroxylation and demethylation. Twenty to 50 % of the drug is excreted unchanged by the kidneys. Only 5% binding to plasma proteins. Fifty to 80% of the drug is converted by CYPs 1A1, 1A2 and 2E1 to alkylating metabolites. Not listed as CYP-inducer or CYP-inhibitor. Ineractions with CYP-metabolism of other drugs not observed.

Cochon et al found dacarbazine to be non-porphyrinogenic in chick embryos (Cochon, A.D. et al, 1997).

No.